This product is a recombinant human antibody that recognizes (both natural and recombinant) human ERBB2.
Figure 1 H2-18 and GDC-0941 synergistically inhibited the growth of both trastuzumab-sensitive and -resistant breast cancer cell lines.
CCK8 assay was used to compare cell proliferation of the breast cancer cell lines SKBR-3 upon indicated treatments.
Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.
Figure 2 H2-18 plus GDC-0941 inhibits the ErbB2 signaling in breast cancer cell lines HCC-1954.
Quantification of Akt phosphorylation in HCC-1954 cells following indicated drug treatments. HCC-1954 cells treated with control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 for 4h were lysed immediately, and the concentrations of phospho-Akt in the cell lysates were determined by a commercially available ELISA kit.
Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.
Figure 3 H2-18 and GDC-0941 in combination induced more cell death than agents alone.
Cell death induced by control IgG, H2-18, GDC-0941, and GDC-0941 plus H2-18 in breast cancer cell line SKBR-3 was examined by flow cytometry using Annexin V/PI double staining detecting kit.
Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.
Figure 4 H2-18 plus GDC-0941 suppressed the in vivo growth of HCC-1954 xenografts.
Tumor volume of HCC-1954 breast tumor xenografts were calculated after treatment with control IgG (10 mg/kg, twice a week, intravenously), H2-18 (10 mg/kg, twice a week, intravenously), GDC-0941 (100 mg/kg, daily, orally), and GDC-0941 (100 mg/kg, daily, orally) plus H2-18 (10 mg/kg, twice a week, intravenously).
Wang, L., Yu, X., Wang, C., Pan, S., Liang, B., Zhang, Y., ... & Yang, Y. (2017). The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget, 8(32), 52877.
Figure 5 H2-18 potently induces apoptosis in ErbB2-overexpressing breast cancer cell lines.
Cell death induced by control IgG, trastuzumab, pertuzumab, trastuzumab plus pertuzumab, and H2-18 in high-ErbB2-expressing (BT-474) was measured by flow cytometry using Annexin V/PI detecting kit.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
Figure 6 H2-18-induced cell death is RIP1-dependent programmed necrosis.
The effect of pan caspase inhibitor Z-VADFMK and autophagy inhibitor bafilomycin A1 on H2-18-induced cell death in HCC-1954 cells.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
Figure 7 H2-18-induced cell death is RIP1-dependent programmed necrosis.
TEM images of HCC-1954 cells treated with control IgG, trastuzumab, pertuzumab, pertuzumab plus trastuzumab, and H2-18 for 48 hours.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
Figure 8 H2-18-induced cell death is RIP1-dependent programmed necrosis.
The effect of Nec-1 on H2-18-induced cell death in HCC-1954 cells.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
Figure 9 ROS and JNK take part in H2-18-induced programmed cell death.
The effect of JNK inhibitor SP600125 or ROS scavenger NAC on H2-18-induced cell death in HCC-1954 cells.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
Figure 10 ROS and JNK take part in H2-18-induced programmed cell death.
JC-1 staining was used to measure the mitochondrial membrane potential in HCC-1954 cells treated with H2-18.
Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., ... & Wang, Y. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. Oncotarget, 7(41), 67129.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B008(A) | Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B008(G) | Recombinant Anti-human ERBB2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B008(T) | Recombinant Anti-human ERBB2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-761 | Anti-ERBB2 Recombinant Antibody (Margetuximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-049CT | Anti-Human HER2/neu Recombinant Antibody (ChA21) | IHC, Inhib, WB, Activ, FC | Chimeric antibody (mouse/human) |
TAB-049CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
TAB-049CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H70 | Anti-Human ERBB2 Recombinant Antibody (Trastuzumab Emtansine) | ELISA, IP, FC, FuncS, Neut, IF, ICC | IgG1 - kappa |
TAB-053 | Anti-Human ERBB2 Recombinant Antibody (Pertuzumab) | FuncS, IF, Neut, ELISA, FC, IP, WB | IgG1 - kappa |
TAB-050CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (HuA21) | ELISA, WB | Humanized antibody |
TAB-053CT-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-053CT-S(P)) | ELISA, Inhib, FC | Humanized scFv |
TAB-054CT-S(P) | Humanized Anti-Human HER2/neu Recombinant Antibody scFv Fragment | ELISA, Inhibition, FC | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G022E | Anti-ERBB2 immunotoxin 4D5 (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G022D | Anti-ERBB2 immunotoxin 4D5 (scFv)-DT | Cytotoxicity assay, Function study | |
AGTO-G022G | Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel | Cytotoxicity assay, Function study | |
AGTO-G022R | Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA | Cytotoxicity assay, Function study | |
AGTO-G022S | Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-085 | Human Anti-ERBB2 Recombinant Antibody (PFBL-085) | ELISA, WB, FuncS | Human Fab |
PFBL-126 | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (PFBL-126) | ELISA, WB, FuncS | Human Fab |
PFBL-463 | Human Anti-ERBB2 Recombinant Antibody (clone mAb37); Fab Fragment | WB | Human Fab |
PSBW-161 | Mouse Anti-ERBB2 Recombinant Antibody (clone chA21); scFv Fragment | FC, WB | Mouse scFv |
HPAB-0733LY-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone AH06); Fab Fragment | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PNBL-066 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr3) | SPR | Llama VHH |
PNBL-067 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr6) | SPR | Llama VHH |
PNBL-069 | Recombinant Anti-HER2 VHH Single Domain Antibody (huMAb4D5-5) | ELISA | Llama VHH |
TAB-032CT | Anti-Human HER2/neu Therapeutic Single Domain Antibody | WB | Single domain antibody |
TAB-046CT | Anti-Human HER2/neu Therapeutic Single Domain Antibody (Gr3) | ELISA, Inhibition, FC | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-034CT | Anti-Human HER2/neu Recombinant Antibody (pertuzumab ) | WB | |
TAB-036CT | Anti-Human HER2/neu Recombinant Antibody (6B2) | ELISA, WB | |
TAB-037CT | Anti-Human HER2/neu Recombinant Antibody (7C2/7F3) | ELISA, WB | |
TAB-270CQ | Mouse Anti-ERBB2 Recombinant Antibody (TAB-270CQ) | WB, Inhib | Mouse IgG |
TAB-270CQ-S(P) | Mouse Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-270CQ-S(P)) | WB, Inhib | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-042CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (CRX01) | WB | Human antibody |
TAB-043CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-043CT-F(E)) | ELISA, Inhibion | Human Fab |
TAB-044CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (MIL5) | WB | Human antibody |
TAB-055CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment | WB | Human antibody |
TAB-056CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-056CT-F(E)) | WB | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-024LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Mouse antibody |
Gly-039LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-117LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-118LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Mouse antibody |
Gly-145LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-146LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-147LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-177LC | Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0195MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0695MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0779MZ | Chicken Anti-ErbB2 Polyclonal IgY | ICC, IF, IHC, IP | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-737CQ | Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) | Block, IP, IF, FC | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1178 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone DS1178AB) | IHC-P, IHC-Fr | Rabbit IgG |
MOR-4586 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH99DS) | WB | Rabbit IgG |
MOR-4587 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH100DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0132CQ | Mouse Anti-ERBB2 Recombinant Antibody (clone SER4) | ELISA | Mouse IgG1 |
HPAB-0608LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0608LY) | ELISA, Inhib, WB, FC | Humanized IgG1 |
HPAB-0609LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0609LY) | ELISA, Inhib | Humanized IgG1 |
HPAB-0610LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0610LY) | ELISA, Inhib | Humanized IgG1 |
HPAB-M0073-YC | Human Anti-ERBB2 Recombinant Antibody (HPAB-M0073-YC) | ELISA, FC | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-468CQ | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-053 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-761 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-005 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0170JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6VLF); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0171JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6L1); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0172JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H2); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0173JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H211); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0359JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone FRc13); scFv Fragment | DB, ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for HPAB-0679YY. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.